Shire bags paediatric label expansion for Cinryze in the US
US regulators have approved a label expansion for Shire’s Cinryze, allowing its use in children aged six and above with hereditary angioedema.
Read More
Tag: C1 inhibitor
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
